Cargando…
Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 continues to threaten public health. The virus is causing breakthrough infections in vaccinated individuals. Also, scarce information is available about cutaneous manifestations after severe acute respiratory syndrome coronavirus 2 infectio...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156422/ https://www.ncbi.nlm.nih.gov/pubmed/37138300 http://dx.doi.org/10.1186/s13256-023-03904-2 |
_version_ | 1785036536994070528 |
---|---|
author | Ciuoderis, Karl Perez, Laura Alvarez, Catalina Usuga, Jaime Carvajal, Leidi Cardona, Andrés Maya, Maria A. Cloherty, Gavin Hernandez-Ortiz, Juan P. Osorio, Jorge E. |
author_facet | Ciuoderis, Karl Perez, Laura Alvarez, Catalina Usuga, Jaime Carvajal, Leidi Cardona, Andrés Maya, Maria A. Cloherty, Gavin Hernandez-Ortiz, Juan P. Osorio, Jorge E. |
author_sort | Ciuoderis, Karl |
collection | PubMed |
description | BACKGROUND: Severe acute respiratory syndrome coronavirus 2 continues to threaten public health. The virus is causing breakthrough infections in vaccinated individuals. Also, scarce information is available about cutaneous manifestations after severe acute respiratory syndrome coronavirus 2 infection. CASE PRESENTATION AND FINDINGS: A case of a triple-vaccinated (Pfizer) 37-year-old Hispanic American (Colombian) male who developed urticaria after Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 breakthrough infection is described. Virus isolation and whole genome sequencing along with immune and molecular assays were performed. Dermatological manifestations (skin rash and urticaria) after Omicron BA.5.1 infection were observed. Sequence analysis of the Omicron BA.5.1 isolate also revealed several important mutations. Hemogram analysis revealed leukocytosis and neutrophilia. Serology testing revealed anti-spike immunoglobulin G serum titers but negative detection of immunoglobulin M at 10 days after symptom onset. Anti-nucleocapsid, anti-spike 1 immunoglobulin G, anti-spike trimer, and anti-receptor-binding-domain immunoglobulin G and immunoglobulin E sera were detected at different titers 10 days after symptom onset. Several serum levels of chemokines/cytokines (Interferon-α, interferon-γ, interleukin-12/interleukin-23p40, interleukin-18, interferon gamma-induced protein-10, monocyte chemoattractant protein-1, monokine induced by gamma, macrophage inflammatory protein-1α, chemokine (C-C motif) ligand-5 , tumor necrosis factor-β1, Tumor necrosis factor-α) were detected, but interleukin-2, interleukin-4, interleukin-6, interleukin-8, and interleukin-17A were below the limit of detection. INTERPRETATION AND CONCLUSIONS: To our knowledge, this is the first study describing skin effects of a severe acute respiratory syndrome coronavirus 2 Omicron BA.5 variant breakthrough infection in a triple-vaccinated patient in Colombia. Several important mutations were found in the spike glycoprotein of the virus isolated; these mutations are associated with immune evasion and changes in antigenic properties of the virus. Physicians overseeing coronavirus disease 2019 cases should be aware of the potential skin effects of the infection. Pathogenesis of severe acute respiratory syndrome coronavirus 2 infection and its association with proinflammatory cytokines and chemokines may enhance the development of urticaria and other skin manifestations in immunized individuals. However, further studies are needed to better understand the complexity of coronavirus disease in such situations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13256-023-03904-2. |
format | Online Article Text |
id | pubmed-10156422 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101564222023-05-05 Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report Ciuoderis, Karl Perez, Laura Alvarez, Catalina Usuga, Jaime Carvajal, Leidi Cardona, Andrés Maya, Maria A. Cloherty, Gavin Hernandez-Ortiz, Juan P. Osorio, Jorge E. J Med Case Rep Case Report BACKGROUND: Severe acute respiratory syndrome coronavirus 2 continues to threaten public health. The virus is causing breakthrough infections in vaccinated individuals. Also, scarce information is available about cutaneous manifestations after severe acute respiratory syndrome coronavirus 2 infection. CASE PRESENTATION AND FINDINGS: A case of a triple-vaccinated (Pfizer) 37-year-old Hispanic American (Colombian) male who developed urticaria after Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 breakthrough infection is described. Virus isolation and whole genome sequencing along with immune and molecular assays were performed. Dermatological manifestations (skin rash and urticaria) after Omicron BA.5.1 infection were observed. Sequence analysis of the Omicron BA.5.1 isolate also revealed several important mutations. Hemogram analysis revealed leukocytosis and neutrophilia. Serology testing revealed anti-spike immunoglobulin G serum titers but negative detection of immunoglobulin M at 10 days after symptom onset. Anti-nucleocapsid, anti-spike 1 immunoglobulin G, anti-spike trimer, and anti-receptor-binding-domain immunoglobulin G and immunoglobulin E sera were detected at different titers 10 days after symptom onset. Several serum levels of chemokines/cytokines (Interferon-α, interferon-γ, interleukin-12/interleukin-23p40, interleukin-18, interferon gamma-induced protein-10, monocyte chemoattractant protein-1, monokine induced by gamma, macrophage inflammatory protein-1α, chemokine (C-C motif) ligand-5 , tumor necrosis factor-β1, Tumor necrosis factor-α) were detected, but interleukin-2, interleukin-4, interleukin-6, interleukin-8, and interleukin-17A were below the limit of detection. INTERPRETATION AND CONCLUSIONS: To our knowledge, this is the first study describing skin effects of a severe acute respiratory syndrome coronavirus 2 Omicron BA.5 variant breakthrough infection in a triple-vaccinated patient in Colombia. Several important mutations were found in the spike glycoprotein of the virus isolated; these mutations are associated with immune evasion and changes in antigenic properties of the virus. Physicians overseeing coronavirus disease 2019 cases should be aware of the potential skin effects of the infection. Pathogenesis of severe acute respiratory syndrome coronavirus 2 infection and its association with proinflammatory cytokines and chemokines may enhance the development of urticaria and other skin manifestations in immunized individuals. However, further studies are needed to better understand the complexity of coronavirus disease in such situations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13256-023-03904-2. BioMed Central 2023-05-04 /pmc/articles/PMC10156422/ /pubmed/37138300 http://dx.doi.org/10.1186/s13256-023-03904-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Ciuoderis, Karl Perez, Laura Alvarez, Catalina Usuga, Jaime Carvajal, Leidi Cardona, Andrés Maya, Maria A. Cloherty, Gavin Hernandez-Ortiz, Juan P. Osorio, Jorge E. Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report |
title | Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report |
title_full | Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report |
title_fullStr | Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report |
title_full_unstemmed | Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report |
title_short | Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report |
title_sort | urticaria after breakthrough omicron ba.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (pfizer) patient: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156422/ https://www.ncbi.nlm.nih.gov/pubmed/37138300 http://dx.doi.org/10.1186/s13256-023-03904-2 |
work_keys_str_mv | AT ciuoderiskarl urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport AT perezlaura urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport AT alvarezcatalina urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport AT usugajaime urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport AT carvajalleidi urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport AT cardonaandres urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport AT mayamariaa urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport AT clohertygavin urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport AT hernandezortizjuanp urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport AT osoriojorgee urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport |